Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662332 · ClinicalTrials.gov registry record · Phase 3
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
A Phase 3 study of Type 2 Diabetes and T2D, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
- 20
- Study locations
NCT05662332 is a Phase 3 study of Type 2 Diabetes and T2D that has completed, run by Eli Lilly and Company. The registered enrollment target is 795 participants, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05662332, a Phase 3 study of Type 2 Diabetes and T2D, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who are starting basal insulin therapy for the first time.
Conditions Studied
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Efsitora Alfa
Study Locations (20)
California
- AMCR Institute - Escondido
- Velocity Clinical Research, Gardena - Gardena
- National Research Institute - Huntington Park - Huntington Park
- National Research Institute - Wilshire - Los Angeles
- Diabetes Associates Medical Group - Orange
- Encompass Clinical Research - Spring Valley
- Millennium Clinical Trials - Thousand Oaks
- University Clinical Investigators, Inc. - Tustin
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
- Suncoast Research Group - Miami
- Clinical Research of West Florida - Tampa
Alabama
- Cahaba Research - Birmingham
- Syed Research Consultants Llc - Sheffield
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- Chase Medical Research, LLC - Waterbury
Georgia
- Center for Advanced Research & Education - Gainesville
Hawaii
- Pacific Diabetes & Endocrine Center - Honolulu
Illinois
- Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2023-01-14 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662332
The ClinicalTrials.gov registry entry for NCT05662332 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 795 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (28% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT05662332 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05662332 about?
NCT05662332 is a clinical study titled "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)". The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who are starting basal insulin therapy for the first time.
What is the current status of trial NCT05662332?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2023-01-14. Estimated completion is 2024-07-19.
What conditions does trial NCT05662332 study?
This clinical trial studies the following conditions: Type 2 Diabetes, T2D.
What interventions are being tested in trial NCT05662332?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Efsitora Alfa (DRUG).
Who is sponsoring clinical trial NCT05662332?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662332 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.